Drug intelligence / Profile preview

GLCP-048-1

Development stage: Preclinical
Lead developer: Galenicap
Modality: Small Molecules
Administration: Oral

Overview

GLCP-048-1 is a small molecule P2Y12 receptor antagonist being developed by Galenicap for the prevention of secondary stroke. The drug targets the P2Y12 receptor, a G protein-coupled receptor found on the surface of platelets that is essential for adenosine diphosphate (ADP)-induced platelet aggregation. By inhibiting this receptor, GLCP-048-1 prevents the activation of the glycoprotein IIb/IIIa complex, thereby reducing platelet thrombus formation. This antiplatelet mechanism is intended to provide a therapeutic option for patients at risk of recurrent ischemic events following an initial stroke.

Targets

P2Y12 (Purinergic P2Y12 receptor)

Beyond the preview

Go deeper on GLCP-048-1.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on GLCP-048-1.

Explore the full profile